In the first large-scale study of its kind, researchers at Kaiser Permanente and the University of California San Francisco found that rates of dementia risk vary across racial and ethnic groups.
In the first large-scale study of its kind, researchers at Kaiser Permanente and the University of California San Francisco (UCSF) found that rates of dementia risk vary across racial and ethnic groups.
Though similar studies on dementia risk have been performed in the past, they have only compared 1 or 2 racial/ethnic groups. In order to better represent the full diversity of the US populace, this is the first direct comparison of dementia rates among 6 different groups: African-Americans/Blacks, American Indians, Alaska Natives (AIAN), Latinos/Hispanics, Pacific Islanders/Native Hawaiians, non-Latino Whites, and Asian-Americans.
Elizabeth Rose Mayeda, PhD, et al. looked at 274,283 members of Kaiser Permanente Northern California (KPNC), an integrated healthcare delivery system in California, who were aged 60 years and older as of January 1, 1996, and had no dementia diagnosis as of January 1, 2000.
The researchers followed these cohort members for incident dementia until end of KPNC membership, death, or end of study period on December 31, 2013. Dementia diagnoses were identified from electronic medical records during this 14-year period based on the International Classification of Diseases, 9th Revision. Those who identified as Other or Multiracial were excluded due to small sample size. All members had equal access to healthcare. Researchers adjusted for healthcare utilization and comorbidities in health conditions including depression, hypertension, diabetes, stroke and cardiovascular disease.
The study found that age-adjusted dementia incidence rates were highest among African-Americans and AIANS; intermediate for Latinos, Pacific Islanders, and Whites; and lowest for Asian-Americans. In most groups, rates were similar for women and men until the age of 90, when rates became higher for women; this difference was statistically significant for Whites.
According to the observations within this study, the following pattern has been predicted for individuals who survive dementia-free to age 65 that will be diagnosed with dementia over the next 25 years: 38% of African-Americans, 35% of AIANs, 32% of Latinos, 30% of Whites, 28% of Asian-Americans, and 25% of Pacific Islanders. Adjustments for healthcare utilization and comorbidities did not substantially explain differences in dementia incidence.
The researchers wrote that it is “unclear if these differences are due to genetic or social and behavior factors, but if social and behavior factors are the primary pathways, these findings suggest substantial reductions in dementia incidence are possible.”
Future research should incorporate the identification of life course determinants of the observed disparities, neuroimaging measures of the observed disparities, evaluating heterogeneity within racial/ethnic groups, and examining dementia outcomes after diagnosis.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More